Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for InMed Pharmaceuticals (INM) over the last 5 years, with Jun 2025 value amounting to $61,410.

  • InMed Pharmaceuticals' Gains from Investment Securities fell 67.76% to $60,356 in Q3 2025 from the same period last year, while for Sep 2025 it was $60,356, marking a year-over-year decrease of 94.77%. This contributed to the annual value of $61,410 for FY2025, which is 82.11% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $61,410 for FY2025, which was up 82.11% from $33,722 recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' Gains from Investment Securities peaked at $102,642 during FY2023, and registered a low of $14,161 during FY2021.
  • For the 3-year period, InMed Pharmaceuticals' Gains from Investment Securities averaged around $65,925, with its median value being $61,410 (2025).
  • In the last 5 years, InMed Pharmaceuticals' Gains from Investment Securities soared by 333.81% in 2022 and then plummeted by 67.15% in 2024.
  • Yearly analysis of 5 years shows InMed Pharmaceuticals' Gains from Investment Securities stood at $14,161 in 2021, then skyrocketed by 333.81% to $61,432 in 2022, then skyrocketed by 67.08% to $102,642 in 2023, then plummeted by 67.15% to $33,722 in 2024, then spiked by 82.11% to $61,410 in 2025.